Gilead Sciences

Gilead Sciences, a Pharmaceutical Preparation Manufacturing company based in the US, reported its most recent carbon emissions for 2025. Its Scope 1 emissions were approximately 50,346,000 kg CO2e, Scope 2 market-based emissions were about 45,000 kg CO2e, and Scope 3 emissions totalled approximately 1,355,943,000 kg CO2e. In 2024, the company's Scope 1 emissions were around 53,901,000 kg CO2e, Scope 2 market-based emissions were about 17,096,000 kg CO2e, and Scope 3 emissions were approximately 1,391,582,000 kg CO2e. For 2023, Gilead Sciences disclosed Scope 1 emissions of approximately 56,435,000 kg CO2e and Scope 2 market-based emissions of about 22,667,000 kg CO2e, but Scope 3 data was not provided.

Gilead Sciences has committed to several climate reduction targets. The company aims to reduce its absolute Scope 1 and Scope 2 GHG emissions by 46% by 2030, using a 2019 baseline. Furthermore, Gilead Sciences intends to achieve carbon net-zero operational GHG emissions (covering Scope 1 and Scope 2) by 2030. These commitments align with Science Based Targets initiative (SBTi) guidance, with the Scope 1 and 2 targets being consistent with reductions required to keep warming to 1.5°C. Additionally, Gilead Sciences has an SBTi commitment to reduce absolute Scope 3 GHG emissions by 15% by 2030, also from a 2019 base year.